Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697858 | 0.83 | GAA (0.50) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL4397787 | 0.83 | GAA (0.50) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL13225976 | 0.83 | GAA (0.50) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL13225973 | 0.81 | GAA (0.48) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL8599636 | 0.81 | GAA (0.48) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL13225974 | 0.81 | GAA (0.48) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL1933219 | 0.81 | GAA (0.48) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL1231230 | 0.79 | GAA (0.47) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL9754770 | 0.78 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL22315110 | 0.78 | GAA (0.45) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20180221514-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-08-09 | — | — | US | disclosed |
| US-9943613-B2 | DAB-4 linked nitroxide citrate, useful as MRI contrast agent | NITROSCI PHARMACEUTICAL, INC. | 2018-04-17 | — | — | US | disclosed |
| WO-2017031239-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20150273087-A1 | DAB-4 LINKED NITROXIDE CITRATE, USEFUL AS MRI CONTRAST AGENT | NITROSCI PHARMACEUTICAL, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150273087-A1 | DAB-4 LINKED NITROXIDE CITRATE, USEFUL AS MRI CONTRAST AGENT | NITROSCI PHARMACEUTICAL, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20100260684-A1 | USE OF 3-ALKANOYLOXYMETHOXYCARBONYL NITROXIDE ESTERS AS OXIMETRY PROBES FOR MEASUREMENT OF OXYGEN STATUS IN TISSUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-14 | — | — | US | disclosed |
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS | 2009-08-13 | — | — | US | disclosed |
| US-5104641-A | Injecting into blood or joints | M.R.I., INC. (US) | 1992-04-14 | — | — | US | disclosed |
| WO-1991013351-A1 | METHOD FOR ENHANCING NUCLEAR MAGNETIC RESONANCE IMAGING USING A NITROXIDE | M.R.I., INC. (US) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203699-A1 | AMINOMETHYLPYRIDINE DERIVATIVES, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | TPMT, QDPR, HNMT | GAA 1353/4885L3MBTL1 4820/4885KDM4E 556/4885 |
| US-20150273087-A1 | DAB-4 LINKED NITROXIDE CITRATE, USEFUL AS MRI CONTRAST AGENT | DAB2IP, PDCD4, PADI4 | GAA 715/4885L3MBTL1 3098/4885KDM4E 578/4885 |
| US-20180221514-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | APP, APBA1, CRYAB | GAA 1049/4885L3MBTL1 3427/4885KDM4E 3581/4885 |
| US-20100260684-A1 | USE OF 3-ALKANOYLOXYMETHOXYCARBONYL NITROXIDE ESTERS AS OXIMETRY PROBES FOR MEASUREMENT OF OXYGEN STATUS IN TISSUES | APEH, LPO, ALKBH3 | GAA 751/4885L3MBTL1 1004/4885KDM4E 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.